EGFR and neoplasm: Next-generation tumor-specific EGFR-targeted antibodies (ABT-806) [11] and their antibody-drug conjugates (Table 1) [12–14] represent promising alternative approaches because these agents enable tumor-selective EGFR-targeting as well as subsequent delivery of the cytotoxic payload independent of EGFR inhibition, and eliminate the systemic side effects associated with exposures to conventional anti-EGFR agents and cytotoxic chemotherapy.